ACAmmar Ahmed Chaudhry

Ammar Ahmed Chaudhry

*This is an algorithmically generated author record based on publicly available information.

Ammar Ahmed Chaudhry has a total of 115 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figure S1 from Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT)

    by Ferdinandos Skoulidis, Salma K. Jabbour, Edward B. Garon, Puneeth Iyengar, Giorgio Scagliotti, Loïc Ferrer, Guillaume Etchepare, Olivier Gallinato, Jérôme Faure, Paul Bernard, et al.

    Supplementary Figure 1. Super T-learner architecture. The active arm refers to treatment with tremelimumab plus durvalumab and chemotherapy while the control arm refers to durvalumab plus chemotherapy

  • Open Access

    Supplementary Figure S2 from Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT)

    by Ferdinandos Skoulidis, Salma K. Jabbour, Edward B. Garon, Puneeth Iyengar, Giorgio Scagliotti, Loïc Ferrer, Guillaume Etchepare, Olivier Gallinato, Jérôme Faure, Paul Bernard, et al.

    Supplementary Figure 2. Overall survival in patient subgroups who received tremelimumab plus durvalumab and chemotherapy or durvalumab plus chemotherapy (analysis set 1).

  • Open Access

    Supplementary Methods from Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT)

    by Ferdinandos Skoulidis, Salma K. Jabbour, Edward B. Garon, Puneeth Iyengar, Giorgio Scagliotti, Loïc Ferrer, Guillaume Etchepare, Olivier Gallinato, Jérôme Faure, Paul Bernard, et al.

  • Open Access

    Supplementary Figure S3 from Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT)

    by Ferdinandos Skoulidis, Salma K. Jabbour, Edward B. Garon, Puneeth Iyengar, Giorgio Scagliotti, Loïc Ferrer, Guillaume Etchepare, Olivier Gallinato, Jérôme Faure, Paul Bernard, et al.

    Supplementary Figure 3. Partial dependence plots (PDPs) for (A) Model 4, analysis set 2 (clinical and radiomics); (B) Model 7, analysis set 3 (clinical and genomics); (C) Model 19, analysis set 6 (clinical and genomics, non-squamous patients only). The PDPs show the predicted CATE against the selected feature, by averaging the model's predictions over all patients with that feature set to a specific value and all other features held constant. Panel A shows PDPs for the top 5 features in Figure 3A, panel 3. Panel B shows PDPs for the top 5 features in Figure 3B, panel 3. Panel C shows PDPs for the top 5 features in Figure 3C, panel 3.

  • Open Access

    Supplementary Tables S1-S11 from Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT)

    by Ferdinandos Skoulidis, Salma K. Jabbour, Edward B. Garon, Puneeth Iyengar, Giorgio Scagliotti, Loïc Ferrer, Guillaume Etchepare, Olivier Gallinato, Jérôme Faure, Paul Bernard, et al.

    Supplementary Table 1. Time-to-event models’ hyperparameter space for Bayesian optimization. Supplementary Table 2. Baseline characteristics for patients included in analysis set 2. Supplementary Table 3. Baseline characteristics for patients included in analysis set 3. Supplementary Table 4. Baseline characteristics for patients included in analysis set 4. Supplementary Table 5. Baseline characteristics for patients included in analysis set 5. Supplementary Table 6. Baseline characteristics for patients included in analysis set 6. Supplementary Table 7. Distribution of missing values for all clinical features. Supplementary Table 8. Representativeness of study participants Supplementary Table 9. Integrated AUC between 0 and 24 months for all numerical features (analysis set 1) Supplementary Table 10. Wald test P-values for all categorical features, ranked according to P-values in the tremelimumab plus durvalumab and chemotherapy arm (analysis set 1) Supplementary Table 11. Group statistics for the 50% of patients with higher/lower treatment benefit (from addition of tremelimumab to durvalumab and chemotherapy) identified by the best performing model (Model 7) with deep dive in STK11, KRAS, and KEAP1 mutations.

  • Open Access

    Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT)

    by Ferdinandos Skoulidis, Salma K. Jabbour, Edward B. Garon, Puneeth Iyengar, Giorgio Scagliotti, Loïc Ferrer, Guillaume Etchepare, Olivier Gallinato, Jérôme Faure, Paul Bernard, et al.

    Purpose: POSEIDON (NCT03164616) was a randomized, open-label, multicenter phase III trial comparing first-line durvalumab with or without tremelimumab in combination with chemotherapy versus chemotherapy alone in patients with metastatic non–small cell lung cancer (NSCLC). Overall survival (OS) and progression-free survival were significantly increased in the tremelimumab plus durvalumab and chemotherapy arm. We conducted a post hoc analysis (TRIDENT) to identify patients who may receive greater OS benefit from the addition of tremelimumab to durvalumab and chemotherapy. Experimental Design: This analysis included clinical, genomic, and radiomic data from the POSEIDON trial (data cutoff March 12, 2021). Machine learning models leveraging multimodal data were trained to identify subpopulations of patients who benefit from the addition of tremelimumab to first-line durvalumab and chemotherapy. Results: Using clinical and genomic data, the model was able to predict treatment benefit from adding tremelimumab to first-line durvalumab and chemotherapy, with the top ranked 50% of patients with nonsquamous tumors achieving a hazard ratio of 0.56 (95% confidence interval, 0.33–0.97). EGFR wild type, FGFR3 wild type, CDKN2A wild type, KRAS mutations, and STK11 mutations were the factors most associated with higher OS benefit. Conclusions: By utilizing machine learning models to analyze POSEIDON data, we yielded genetic signatures identifying patients with nonsquamous metastatic NSCLC who may derive greater OS benefit from the addition of tremelimumab to first-line durvalumab and chemotherapy. Such approaches could be used in the future to enhance precision in tailoring therapies for individual patients.

  • Top Cited Papers
    Open Access

    CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer

    by Pasi A. Jänne, David Planchard, Kunihiko Kobayashi, Ying Cheng, Chee Khoon Lee, Natalia Valdiviezo, Konstantin Laktionov, Tsung-Ying Yang, Yan Yu, Terufumi Kato, et al.

    PURPOSE: We report CNS efficacy of first-line osimertinib plus chemotherapy versus osimertinib monotherapy in patients with epidermal growth factor receptor ( EGFR)–mutated advanced non–small-cell lung cancer (NSCLC) from the phase III FLAURA2 study according to baseline CNS metastasis status. METHODS: Patients were randomly assigned to osimertinib plus platinum-pemetrexed (combination) or osimertinib monotherapy until disease progression or discontinuation. Brain scans were performed in all patients at baseline and progression and at scheduled assessments until progression for patients with baseline CNS metastases; scans were assessed by neuroradiologist CNS blinded independent central review (BICR). RESULTS: On the basis of baseline CNS BICR, 118 of 279 (combination) and 104 of 278 (monotherapy) randomly assigned patients had ≥one measurable and/or nonmeasurable CNS lesion and were included in the CNS full analysis set (cFAS); 40 of 118 and 38 of 104 had ≥one measurable target CNS lesion and were included in the post hoc CNS evaluable-for-response set (cEFR). In the cFAS, the hazard ratio (HR) for CNS progression or death was 0.58 (95% CI, 0.33 to 1.01). In patients without baseline CNS metastases, the HR for CNS progression or death was 0.67 (95% CI, 0.43 to 1.04). In the cFAS, CNS objective response rates (ORRs; 95% CI) were 73% (combination; 64 to 81) versus 69% (monotherapy; 59 to 78); 59% versus 43% had CNS complete response (CR). In the cEFR, CNS ORRs (95% CI) were 88% (73 to 96) versus 87% (72 to 96); 48% versus 16% had CNS CR. CONCLUSION: Osimertinib plus platinum-pemetrexed demonstrated improved CNS efficacy compared with osimertinib monotherapy, including delaying CNS progression, irrespective of baseline CNS metastasis status. These data support this combination as a new first-line treatment for patients with EGFR-mutated advanced NSCLC, including those with CNS metastases.


  • Top Cited Papers
    Open Access

    Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

    by Matthew G. Mei, Hun Ju Lee, Joycelynne M. Palmer, Robert Chen, Ni-Chun Tsai, Lu Chen, Kathryn McBride, D. Lynne Smith, Ivana Melgar, Joo Y. Song, et al.

    This phase 2 trial evaluated PET-adapted nivolumab alone or in combination with ifosfamide, carboplatin, and etoposide (NICE) as first salvage therapy and bridge to autologous hematopoietic cell transplantation (AHCT) in relapsed/refractory (RR) classical Hodgkin lymphoma (cHL). Patients with RR cHL received 240 mg nivolumab every 2 weeks for up to 6 cycles (C). Patients in complete response (CR) after C6 proceeded to AHCT, whereas patients with progressive disease at any point or not in CR after C6 received NICE for 2 cycles. The primary endpoint was CR rate per the 2014 Lugano classification at completion of protocol therapy. Forty-three patients were evaluable for toxicity; 42 were evaluable for response. Thirty-four patients received nivolumab alone, and 9 patients received nivolumab+NICE. No unexpected toxicities were observed after nivolumab or NICE. After nivolumab, the overall response rate (ORR) was 81%, and the CR rate was 71%. Among 9 patients who received NICE, all responded, with 8 (89%) achieving CR. At the end of protocol therapy, the ORR and CR rates were 93% and 91%. Thirty-three patients were bridged directly to AHCT, including 26 after Nivo alone. The 2-year progression-free survival (PFS) and overall survival in all treated patients (n = 43) were 72% and 95%, respectively. Among 33 patients who bridged directly to AHCT, the 2-year PFS was 94% (95% CI: 78-98). PET-adapted sequential salvage therapy with nivolumab/nivolumab+NICE was well tolerated and effective, resulting in a high CR rate and bridging most patients to AHCT without chemotherapy. This trial was registered at www.clinicaltrials.gov #NCT03016871.


  • Open Access

    Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64–labeled daratumumab

    by Amrita Krishnan, Vikram Adhikarla, Erasmus K. Poku, Joycelynne Palmer, Ammar Chaudhry, Van Eric Biglang-Awa, Nicole Bowles, Nitya Nathwani, Michael Rosenzweig, Firoozeh Sahebi, et al.

    18F-Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is one of the most widely used imaging techniques to detect multiple myeloma (MM). Intracellular FDG uptake depicts in vivo metabolic activity, which can be seen in both malignant and nonmalignant cells, resulting in limited sensitivity and specificity. Our group showed preclinically that tracing MM dissemination using a CD38-directed human antibody, daratumumab, that is radioconjugated with 64Cu via the chelator DOTA (64Cu-daratumumab), led to improved sensitivity and specificity over that of FDG. Here, we report the results of a phase 1 trial designed to (1) assess the safety and feasibility of 64Cu-daratumumab PET/CT and (2) preliminarily evaluate and characterize the ability of 64Cu-daratumumab to accurately detect or exclude MM lesions. A total of 12 daratumumab-naive patients were imaged. Prior to the injection of 15 mCi/5 mg of 64Cu-daratumumab, patients were treated with 0 (n = 3), 10 (n = 3), 45 (n = 3), or 95 mg (n = 3) of unlabeled daratumumab to assess its effect on image quality. No significant adverse events were observed from either unlabeled daratumumab or 64Cu-daratumumab. Of the dose levels tested, 45 mg unlabeled daratumumab was the most optimal in terms of removing background signal without saturating target sites. 64Cu-daratumumab PET/CT provided safe whole-body imaging of MM. A trial comparing the sensitivity and specificity of 64Cu-daratumumab PET/CT with that of FDG PET/CT is planned. This trial was registered at www.clinicaltrials.gov as #NCT03311828.


  • Open Access

    Detection of the Stellate and Thoracic Sympathetic Chain Ganglia with High-Resolution 3D-CISS MR Imaging

    by A. Chaudhry, A. Kamali, D.A. Herzka, K.C. Wang, J.A. Carrino, A.M. Blitz

    BACKGROUND AND PURPOSE: Despite the importance of the sympathetic nervous system in homeostasis and its putative role in various disease states, little is known regarding our ability to image the sympathetic chain and sympathetic chain ganglia, perhaps owing to their small size. In this retrospective study, we sought to evaluate the normal anatomy of the sympathetic chain ganglia and assess the detectability of the sympathetic chain and sympathetic chain ganglia on high-resolution 3D-CISS images. MATERIALS AND METHODS: This study included 29 patients who underwent 3D-CISS MR imaging of the thoracic spine for reasons unrelated to abnormalities of the sympathetic nervous system. Patients with a prior spinal operation or visible spinal pathology were excluded. The sympathetic chain ganglia were evaluated using noncontrast 3D-CISS MR imaging. Statistical analyses included t tests and measures of central tendency. The Cohen κ statistic was calculated to evaluate interrater reliability. RESULTS: The stellate ganglion and thoracic chain ganglia were identified in all subjects except at the T10–T11 and T11–T12 levels. The stellate ganglion was found inferomedial to the subclavian artery and anterior and inferior to the transverse process of C7 in all subjects. Thoracic sympathetic chain ganglia were identified ventral to the costovertebral junction in all subjects from T2 to T10. There was strong interobserver agreement for the detection of the sympathetic chain ganglia with κ > 0.80. The size, shape, and location of these structures corresponded with gross anatomic and surgical observations. CONCLUSIONS: The thoracic sympathetic chain ganglia can be identified on precontrast 3D-CISS MR imaging. This technique may aid in the initial evaluation of stellate ganglion and/or sympathetic chain ganglia size and signal change for comparison in future studies.